1. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
- Author
-
David Marcilla, Cristobal Muñoz-Casares, Nadia Hindi, Antonio Gutierrez, Alberto Sánchez-Camacho, Javier Martin-Broto, Sara Chacon, P. Sancho, Paloma Santos, Johanna Benedetti, Paloma Sanchez-Bustos, Javier Peinado, Victor Encinas, Irene Carrasco García, David S. Moura, Inmaculada Rincón, [Hindi,N, Carrasco García,I, Sánchez-Camacho,A, Benedetti,J, Sancho,P, Santos,P, Martin-Broto,J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain. [Hindi,N, Sánchez-Bustos,P, Moura,D, Martin-Broto,J] TERABIS Group, IBiS (Instituto de Biomedicina de Sevilla), Sevilla, Spain. [Gutierrez,A] Hematology Department, University Hospital Son Espases, Mallorca, Spain. [Peinado,J, and Rincón,I] Radiation Oncology Department, University Hospital Virgen del Rocio, Sevilla, Spain. [Peinado,J] Biología Molecular del Cáncer, IBiS (Instituto de Biomedicina de Sevilla), Sevilla, Spain. [Peinado,J] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. [Marcilla,D] Pathology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain. [Encinas,V] Musculoskeletal Unit, Radiology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain. [Chacon,S] Musculoskeletal Tumor Unit, Orthopedics Surgery Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain. [Muñoz-Casares,C] Surgery Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
- Subjects
0301 basic medicine ,Advanced soft tissue sarcomas ,Cancer Research ,Antraciclinas ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings] ,medicine.medical_treatment ,Trabectedina ,Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Halogenated::Mustard Compounds::Nitrogen Mustard Compounds::Phosphoramide Mustards::Cyclophosphamide::Ifosfamide [Medical Subject Headings] ,Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma [Medical Subject Headings] ,Diseases::Respiratory Tract Diseases::Respiration Disorders::Dyspnea [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Palliative Care [Medical Subject Headings] ,trabectedin plus radiotherapy ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,advanced soft-tissue sarcoma ,Anatomy::Cells::Cells, Cultured::Cell Line [Medical Subject Headings] ,Anthracyclines ,Trabectedin ,Palliative therapy ,Soft tissue sarcoma ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Radiotherapy [Medical Subject Headings] ,Sarcoma ,Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthacenes::Anthracyclines [Medical Subject Headings] ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cuidados paliativos ,growth-modulation index ,Oncology ,030220 oncology & carcinogenesis ,medicine.drug ,medicine.medical_specialty ,palliative therapy ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,Radioterapia ,Advanced soft-tissue sarcoma ,Anatomy::Cells::Connective Tissue Cells::Macrophages [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings] ,medicine ,In patient ,Ifosfamide ,Growth-modulation index ,Persons::Persons::Age Groups::Adult [Medical Subject Headings] ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Radiation-Sensitizing Agents [Medical Subject Headings] ,business.industry ,Ifosfamida ,Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Pain [Medical Subject Headings] ,Trabectedin plus radiotherapy ,medicine.disease ,Symptomatic relief ,Surgery ,Clinical trial ,Radiation therapy ,Regimen ,030104 developmental biology ,Dyspnea ,Disnea ,business - Abstract
Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin and radiotherapy showed activity in a recently reported clinical trial in this setting. This retrospective series aims to analyze our experience with the same regimen in the real-life setting. We retrospectively reviewed advanced sarcoma patients treated with trabectedin concomitantly with radiotherapy with palliative intent. Growth-modulation index (GMI) was calculated as a surrogate of efficacy. Forty metastatic patients were analyzed. According to RECIST, there was one (2.5%) complete response, 12 (30%) partial responses, 18 (45%) disease stabilizations, and nine (22.5%) progressions. After a median follow-up of 15 months (range 2&ndash, 38), median progression-free survival (PFS) and overall survival (OS) were 7.5 months (95% CI 2.8&ndash, 12.2) and 23.5 months (95% CI 1.1&ndash, 45.8), respectively. Median GMI was 1.42 (range 0.19&ndash, 23.76), and in 16 (53%) patients, it was >, 1.33. In patients with GMI >, 1.33, median OS was significantly longer than in those with GMI 0&ndash, 1.33 (median OS 52.1 months (95% CI not reached) vs. 8.9 months (95% CI 6.3&ndash, 11.6), p = 0.028). The combination of trabectedin plus radiotherapy is an active therapeutic option in patients with advanced STS, especially when tumor shrinkage for symptomatic relief is needed.
- Published
- 2020